Comparative Pharmacology
Head-to-head clinical analysis: CATAFLAM versus MOBIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CATAFLAM versus MOBIC.
CATAFLAM vs MOBIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
50 mg orally three times daily; maximum 150 mg/day.
7.5-15 mg orally once daily. Maximum 15 mg/day.
None Documented
None Documented
Terminal elimination half-life of diclofenac is approximately 1-2 hours. However, for the enteric-coated formulation (Cataflam), the half-life may be slightly prolonged due to slower absorption; clinical relevance is minimal as analgesic duration is 4-8 hours.
Terminal elimination half-life: ~20 hours (range 13–20 h); allows once-daily dosing; prolonged in elderly (25–26 h) and hepatic impairment.
Approximately 50-60% of a single dose is excreted in urine as metabolites (primarily glucuronide conjugates and 4'-hydroxydiclofenac) with <1% unchanged. 30-40% is excreted in feces via bile. Renal clearance is 250-350 mL/min.
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~50% via feces; enterohepatic recirculation occurs.
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug
Nonsteroidal Anti-Inflammatory Drug